Septerna, Inc.

Septerna Inc. is a clinical-stage biotechnology company specializing in the discovery and development of oral small molecule therapies targeting G protein-coupled receptors (GPCRs). Powered by its proprietary Native Complex Platform, the company unlocks challenging GPCR targets to create novel medicines for patients with significant unmet needs. Its wholly-owned pipeline focuses on three key therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Notable programs include the PTH1R program with oral small molecule Parathyroid Hormone 1 Receptor agonists for hypoparathyroidism; SEP-631, an oral MRGPRX2 negative allosteric modulator for chronic spontaneous urticaria and mast cell-driven diseases; the TSHR program for Graves’ disease and thyroid eye disease; and oral single- and multi-incretin receptor agonists for metabolic disorders like obesity and type 2 diabetes. Septerna Inc. advances a deep portfolio of GPCR-targeted candidates, employing novel mechanistic approaches to address diseases across these fields. Founded in 2019 and headquartered in South San Francisco, California, the company drives innovation in GPCR drug discovery through its industrial-scale platform and expert team.